Strand

Private equity firm Quadria Capital led the investment round and was joined by HealthQuad Fund and Heritas Venture Fund.

The two companies, who announced the merger in January, said they could not complete the terms of their deal in a timely enough manner.

The Strand Center for Genomics and Personalized Medicine lab is now accredited in India to perform three of Strand's most popular tests. 

Once the deal is fully concluded, Strand's shareholders will own approximately 68 percent of the new company, while Venaxis shareholders will own 32 percent.

Strand provides a standard of care report that includes a handful of genes and IHC markers within eight days, and the full 152-gene report seven to 12 days later.

The companies anticipate launching the next-generation sequencing-based tests in Russia "in the near future."

Under the terms of the agreement, Tataa will distribute and support Strand's analysis software in Europe and will also use the tool in training programs.

The StrandAdvantage test currently analyzes 48 cancer-related genes on one of the laboratory's three Illumina MiSeq instruments.

The partners will integrate Strand's informatics software with MRI Global's mobile diagnostic labs and co-develop companion diagnostics.

NEW YORK (GenomeWeb) – Bangalore, India-based Leucine Rich Bio has developed and is preparing to launch a new cloud-based software-as-a-service solution dubbed CtoG to help clinical genetics laboratories identify potentially harmful mutations in data from their next-generation sequencing-based te

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.